Expert consensus on pre-treatment of clinical samples by liquid chromatography-tandem mass spectrometry.
10.3760/cma.j.cn112150-20230906-00160
- VernacularTitle:液相色谱-串联质谱法临床样品前处理专家共识
- Collective Name:Grassroots Inspection Technology Standardization Branch of China International Exchange and Promotive Association for Medical and Health Care;Chinese Hospital Association Clinical Laboratory Specialized Committee
- Publication Type:Journal Article
- MeSH:
Humans;
Chromatography, Liquid;
Consensus;
Tandem Mass Spectrometry
- From:
Chinese Journal of Preventive Medicine
2023;57(12):2073-2085
- CountryChina
- Language:Chinese
-
Abstract:
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) combines the advantages of high separation ability of chromatography and high selectivity, specificity and sensitivity of mass spectrometry, making it one of the most vibrant new technologies in the field of clinical testing. However, the analytical performance is often limited by the characteristics of the sample to be measured. Due to the limited anti-contamination capability of the mass spectrometer, biological samples need to be properly pre-processed to effectively improve the detection performance and achieve accurate detection. The main function of pre-treatment is to selectively separate the target analyte from the biological matrix to reduce interference from other matrix components. At the same time, the target analytes can be concentrated and enriched to improve the analytical sensitivity. At present, there are many kinds of clinical sample pre-treatment methods, and several methods are time-consuming and cumbersome, which brings difficulties to laboratory personnel in method selection, development and standardized operation. Therefore, the purpose of this consensus is to provide guidance for the establishment of laboratory methods and facilitate the standardized development of clinical mass spectrometry measurement.
